Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc demonstrates a strong growth trajectory, with expectations of a $10-15 million sequential EBITDA improvement in the third and fourth quarters, culminating in projected figures of $32.5 million for Q3 and $45 million for Q4. The company is capitalizing on its robust cross-selling abilities, upselling risk-based products to large clients, and securing new evergreen contracts, positioning it well for outsized growth in the coming years. Furthermore, with a Medical Expense Ratio (MER) anticipated to improve significantly and top-line growth surpassing the mid-teens revenue growth target, Evolent Health is positioned for substantial profitability and market leadership in specialty-focused value-based care.

Bears say

Evolent Health Inc. is projected to experience a significant decline in revenue, specifically losing approximately $100 million from its legacy Performance Suite, which is contributing to an estimated total revenue of about $850 million for that segment. The company has also lowered its earnings per share (EPS) estimates for fiscal years 2026 and 2027, indicating a reduction in expected profitability from previous forecasts. In addition, while general and administrative costs are expected to decline due to efficiency initiatives, the overall financial outlook remains bleak due to stagnant EBITDA performance, with Q1 targeted at just $20 million and anticipated flat growth in Q2.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.